http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006096985-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49976f12383b3bd0f229afa41817048a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41c9ca28246d9db8e1a8eef06e19fb75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8b6360865fdccd7b86ecec801945d30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ce7d0011b25b5e774477c21f288d118e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fa903c6340209810a71667486e15347 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-10043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-10022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-10021 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 |
| filingDate | 2006-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_142c5b4a4f829e5e646b8c932754665b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bbdaaa55d06a5e77fcd4fa5d62ca2e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3e3c7fbee171f32068fd36f0399eda5 |
| publicationDate | 2006-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2006096985-A1 |
| titleOfInvention | Human endogenous retrovirus with foamy-like properties and uses thereof |
| abstract | The invention relates to the discovery of a human endogenous retrovirus (HERV) family, Type I HERV-K (HML-2) which appear to be active in vitro and in vivo, infectious, and which have the have the salient features and properties of foamy retroviruses. Based on its natural replication in humans, and that it protects the host from viral and tumor transformation, this non-pathogenic endogenous virus could be developed as a replication competent gene therapy vector. It also is expected to have much higher efficacy than other vectors as it crosses the bloodbrain barrier and infects almost all cell types in the host (proliferating or not). It may naturally lyse tumor cells or infected cells, and thus could even be used without genetic modification. Of course, this vector could be used in traditional ways with it ability to replicate genetically removed. In addition to its value as a vector, as it is reactivated with infection, its detection could also be used to monitor the safety of gene therapy (irrespective of vector type used), as well as other biological therapies including vaccination, blood transfusion, transplantation and xenotransplantation. Finally it may be used to screen for new therapeutic and prophylactic treatments for a wide variety of diseases. |
| priorityDate | 2005-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 94.